A novel method for insulin delivery via the intestines, paving the way for oral tablet intake, has been engineered by researchers at Kumamoto University. The findings of this study have been published in the journal Molecular Pharmaceutics (MP).
The prospect of taking insulin orally has been a topic of discussion for well over a century, yet its practical realization has remained elusive until now. The primary obstacle has been the digestive tract’s enzymes, which typically degrade insulin before it can enter the bloodstream, coupled with the intestine’s inability to absorb it effectively. Consequently, individuals diagnosed with diabetes are currently compelled to administer daily injections.
The team, spearheaded by Associate Professor Shingo Ito, introduced the concept of employing a particular cyclic peptide, known as DNP, which possesses the capability to permeate the small intestine wall and facilitate the transport of insulin molecules.
The researchers devised two distinct methodologies. The initial approach involves combining the modified peptide with insulin that has been stabilized using zinc. Trials conducted on murine models of diabetes demonstrated that administering this blend orally resulted in a rapid return of blood sugar levels to normal ranges, a state that was sustained with daily application.
In the second scenario, scientists chemically bonded the peptide and the insulin molecule together into a single entity. This technique proved successful, as the peptide demonstrably aided the hormone in crossing the intestinal barrier.
A significant drawback historically associated with oral insulin was the requirement for extremely high dosages—many times greater than those administered via injection. The new approach has made it feasible to substantially reduce this required amount. The resulting bioavailability registered between 33% and 41% relative to subcutaneous injection, a figure regarded by experts as excellent for comparable delivery systems.
Further refinement of this technology is still necessary. The scientists’ forthcoming objectives include conducting trials on larger animals and models that closely mimic the human intestinal system. Should these subsequent outcomes be validated, this development could signify a major stride toward offering a convenient substitute for injections, thereby enhancing the quality of life for diabetic patients.
About the Author
